Knapp FF, Dash A. Radiopharmaceuticals for therapy. New Delhi: Springer; 2016.
Book
Google Scholar
Lanconelli N, Pacilio M, Lo Meo S, Botta F, Di Dia A, Aroche AT, Pérez MAC, Cremonesi M. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions. Phys Med Biol. 2012; 57:517–33. https://doi.org/10.1088/0031-9155/57/2/517.
Article
CAS
Google Scholar
Reiner D, Blaickner M, Rattay F. Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated with MCNP5. Med Phys. 2009; 36:4890–6. https://doi.org/10.1118/1.3231995.
Article
CAS
Google Scholar
Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013; 31:1977–83. https://doi.org/10.1200/jco.2012.45.6400.
Article
CAS
Google Scholar
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017; 376:125–35. https://doi.org/10.1056/NEJMoa1607427.
Article
CAS
Google Scholar
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [ 177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018; 19:825–33. https://doi.org/10.1016/s1470-2045(18)30198-0.
Article
CAS
Google Scholar
O’Donoghue J, Bardiès M, Wheldon T. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995; 36:1902–9.
PubMed
Google Scholar
de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002; 32:133–40. https://doi.org/10.1053/snuc.2002.31027.
Article
Google Scholar
de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu and 90Y-labeled somatostatin analogs. J Nucl Med. 2005; 46:13.
Google Scholar
Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy. J Nucl Med. 2016; 57:759–64. https://doi.org/10.2967/jnumed.115.170423.
Article
Google Scholar
Uusijärvi H, Bernhardt P, Rösch F, Maecke HR, Forssell-Aronsson E. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. J Nucl Med. 2006; 47:807–14.
PubMed
Google Scholar
Champion C, Quinto MA, Morgat C, Zanotti-Fregonara P, Hindié E. Comparison between three promising β-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease. Theranostics. 2016; 6:1611–8. https://doi.org/10.7150/thno.15132.
Article
CAS
Google Scholar
Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, Türler A, Schibli R. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014; 41:476–85. https://doi.org/10.1007/s00259-013-2563-z.
Article
Google Scholar
Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, Türler A, Fischer E, Schibli R. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Eur J Nucl Med Mol Imaging. 2014; 41:1907–15. https://doi.org/10.1007/s00259-014-2798-3.
Article
Google Scholar
Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 46:1919–30. https://doi.org/10.1007/s00259-019-04345-0.
Article
Google Scholar
Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grünberg J, Hohn A, Köster U, Schibli R, Türler A, Zhernosekov K. The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011; 38:917–24. https://doi.org/10.1016/j.nucmedbio.2011.02.007.
Article
CAS
Google Scholar
Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, Schibli R, Müller C. Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Res. 2016; 6:13. https://doi.org/10.1186/s13550-016-0171-1.
Article
Google Scholar
Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, Vögele A, Schibli R, van der Meulen NP. Production and characterization of no-carrier-added 161Ttb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019; 4:12. https://doi.org/10.1186/s41181-019-0063-6.
Article
Google Scholar
Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, van der Walt NT, Türler A, Schibli R. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β− radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012; 53:1951–9. https://doi.org/10.2967/jnumed.112.107540.
Article
Google Scholar
Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester H-J, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. From bench to bedside—the bad Berka experience with first-in-human studies. Semin Nucl Med. 2019; 49:422–37. https://doi.org/10.1053/j.semnuclmed.2019.06.002.
Article
Google Scholar
Champion C, Zanotti-Fregonara P, Hindié E. Celldose: A Monte Carlo code to assess electron dose distribution S values for 131i in spheres of various sizes. J Nucl Med. 2008; 49:151–7. https://doi.org/10.2967/jnumed.107.045179.
Article
Google Scholar
Hindié E, Champion C, Zanotti-Fregonara P, Rubello D, Colas-Linhart N, Ravasi L, Moretti J-L. Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE". Eur J Nucl Med Mol Imaging. 2009; 36:130–6. https://doi.org/10.1007/s00259-008-0893-z.
Article
Google Scholar
International Commission on Radiological Protection. Nuclear Decay Data for Dosimetric Calculations. ICRP Publication 107. Ann. ICRP2008;38.
Hurst RE, Bastian A, Bailey-Downs L, Ihnat MA. Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Ther Adv Med Oncol. 2016; 8:126–37. https://doi.org/10.1177/1758834015624277.
Article
CAS
Google Scholar
Cortés-Hernández LE, Eslami-S Z, Pantel K, Alix-Panabières C. Molecular and functional characterization of circulating tumor cells: from discovery to clinical application. Clin Chem. 2019. https://doi.org/10.1373/clinchem.2019.303586.
Article
Google Scholar
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat Rev Clin Oncol. 2019; 16:409–24. https://doi.org/10.1038/s41571-019-0187-3.
Article
CAS
Google Scholar
Sahlmann C-O, Homayounfar K, Niessner M, Dyczkowski J, Conradi L-C, Braulke F, Meller B, Beißbarth T, Ghadimi BM, Meller J, Goldenberg DM, Liersch T. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study. Cancer. 2017; 123:638–49. https://doi.org/10.1002/cncr.30390.
Article
CAS
Google Scholar
Cornelissen B. Imaging the inside of a tumour: a review of radionuclide imaging and theranostics targeting intracellular epitopes. J Labelled Comp Radiopharm. 2014; 57:310–6. https://doi.org/10.1002/jlcr.3152.
Article
CAS
Google Scholar
Yorke ED, Williams LE, Demidecki AJ, Heidorn DB, Roberson PL, Wessels BW. Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations. Med Phys. 1993; 20:543–50. https://doi.org/10.1118/1.597050.
Article
CAS
Google Scholar
Schollhammer R, de Clermont Gallerande H, Yacoub M, Quintyn Ranty M-L, Barthe N, Vimont D, Hindié E, Fernandez P, Morgat C. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI Res. 2019; 9:52. https://doi.org/10.1186/s13550-019-0517-6.
Article
Google Scholar
Puncher MR, Blower PJ. Radionuclide targeting and dosimetry at the microscopic level: the role of microautoradiography. Eur J Nucl Med. 1994; 21:1347–65. https://doi.org/10.1007/bf02426701.
Article
CAS
Google Scholar
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell, 4th edn. New York: Garland Science; 2002, p. 197.
Google Scholar
Jevtić P, Edens LJ, Vuković LD, Levy DL. Sizing and shaping the nucleus: mechanisms and significance. Curr Opin Cell Biol. 2014; 28:16–27. https://doi.org/10.1016/j.ceb.2014.01.003.
Article
Google Scholar
Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994; 35:521–30.
CAS
PubMed
Google Scholar
Tamborino G, de Saint-Hubert M, Struelens L, Seoane DC, Ruigrok EAM, Aerts, van Cappellen WA, de Jong M, Konijnenberg MW, Nonnekens J. Cellular dosimetry of [ 177Lu]Lu-DOTA-[Tyr 3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. EJNMMI Phys. 2020; 7:8. https://doi.org/10.1186/s40658-020-0276-5.
Article
Google Scholar
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27:273–82. https://doi.org/10.1007/s002590050034.
Article
CAS
Google Scholar
Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC. Unexpected sensitivity of sst 2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012; 53:1481–9. https://doi.org/10.2967/jnumed.112.102764.
Article
CAS
Google Scholar
Chastel A, Worm DJ, Alves ID, Vimont D, Petrel M, Fernandez S, Garrigue P, Fernandez P, Hindié E, Beck-Sickinger AG, Morgat C. Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. EJNMMI Res. 2020; 10:16. https://doi.org/10.1186/s13550-020-0612-8.
Article
CAS
Google Scholar